LGM
RAPT

Logos Global Management’s RAPT Therapeutics RAPT Stock Holding History

Logos Global Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-93,750
Closed -$23.8M – 65
2021
Q2 		$23.8M Buy
+93,750
New +$17.5M 2% 19

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Logos Global Management's RAPT Position: Q1 2023 in Review

Logos Global Management sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 25,000 shares — an estimated $3.96M sold.

Logos Global Management first reported a position in RAPT in Q2 2020 and held it in 4 quarters. The position peaked at $8.58M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

  • Logos Global Management reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Logos Global Management sold 25,000 RAPT Therapeutics shares in Q1 2023, an estimated $3.96M.
  • Logos Global Management first reported a position in RAPT Therapeutics in Q2 2020 and held it in 4 quarters.
  • Logos Global Management's RAPT Therapeutics position peaked at $8.58M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.